A Multicenter, Post-Market Clinical Follow-up Study of Subjects With the REDAPT™ System Monolithic Sleeveless/Sleeved Stem and/or Fully Porous Acetabular Shell With XLPE Liner and/or Modular Shell Components Previously Implanted

Smith & Nephew, Inc.4 sites in 1 country220 target enrollmentMay 7, 2018

ConditionsHip Replacement

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Hip Replacement
Sponsor: Smith & Nephew, Inc.
Enrollment: 220
Locations: 4
Primary Endpoint: Revision rate
Status: Enrolling By Invitation
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The primary purpose of this study is to demonstrate cumulative revision rate of the REDAPT System Monolithic Sleeveless/Sleeved Stem, Fully Porous Acetabular Shell with XLPE liner, and Modular Shell Components (with or without Staple, Slice and Blade Augments) at 10 years.

Detailed Description

Retrospective-prospective, single arm, multicenter study of subjects previously implanted with the REDAPT System Monolithic Sleeveless/Sleeved Stem and/or Fully Porous Acetabular Shell with XLPE liner and/or Modular Shell Components (with or without Staple, Slice and Blade Augments).

Registry

clinicaltrials.gov

Start Date

May 7, 2018

End Date

July 1, 2034

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Smith & Nephew, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects must meet all of the inclusion criteria to enroll in the study:
•Subject was considered skeletally mature at the time of surgery and was at least 18 years of age.
•Subject has undergone hip arthroplasty with the REDAPT Fully Porous Acetabular Shell with XLPE liner or REDAPT Modular Cup Components (with or without Staple, Slice and Blade Augments), and/or Monolithic Sleeveless Stem, and/or Monolithic Sleeved Stem and are at least 3 months post-implantation at this site.
•Subject required surgery with REDAPT device chosen for one of the following indications:
•Advanced degeneration of the hip joint as result of osteoarthritis, avascular necrosis, posttraumatic arthritis, rheumatoid arthritis, or dysplasia (or any of the composites of these conditions).
•Fracture-dislocation of the hip, femoral neck fracture or trochanteric fractures of the proximal femur with head involvement that are unmanageable using other techniques.
•Revision THA
•Subject is willing to consent to and to follow the study visit schedule (as defined in the study protocol and ICF), by signing the IRB/IEC approved ICF.
•Subject is willing and able to participate in required follow-up visits at the investigational site and to complete study procedures.

Exclusion Criteria

•Subjects meeting any of the following exclusion criteria will be excluded from study participation:
•Subject had an active infection - systemic or at the site of surgery.
•Subject, in the opinion of the PI, has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, mental retardation, drug or alcohol abuse.
•Subject is known to be at risk for loss to follow-up or failure to return for scheduled visits.
•Subject is incarcerated or is pending incarceration.
•Subject is enrolled in another clinical study that would affect the endpoints of the study.

Outcomes

Primary Outcomes

Revision rate

Time Frame: 10 years post-op

REDAPT System Monolithic Sleeveless/Sleeved Stem, Fully Porous Acetabular Shell with XLPE liner and Modular Shell Components (with or without Staple, Slice and Blade Augments) cumulative revision rate for any reason 10 years postoperatively.

Secondary Outcomes

Radiographic assessments(Collect retrospectively from medical records preoperatively and at 1 year, and prospectively at 2, 5, and 10 years post-operatively)
EuroQul Five Dimensions Questionnaire EQ-5D-5L(Collect retrospectively from medical records preoperatively and at 1 year, and prospectively at 2, 5, and 10 years post-operatively)
Functional outcomes as determined by the Hip Disability Osteoarthritis Outcome (HOOS) score(Collect retrospectively from medical records preoperatively and at 1 year, and prospectively at 2, 5, and 10 years post-operatively)